Challenge:
A new venture fund reached out to Alacrita for support with identifying novel pharma assets available for in-licensing, for the purpose of founding a new start-up and enabling the further development of the asset for autoimmune or immunology indications. Modalities of interest included small molecules, gene therapies, or biologics and de-prioritized assets that were IND-ready through phase 3 clinical development were in scope.
Solution:
Alacrita consultants worked closely with the client to identify a stream of opportunities for further evaluation. Given the stage of development of interest, commercial pipeline databases were primarily used as a starting point. Assets identified as potential candidates were selected for outreach and our consultants reviewed and analyzed non-confidential data requested and received from the asset owner to determine fit with client criteria. A high-level summary for each asset of interest was provided to the client to determine whether to enter into further discussions with the asset owner.
After 3 months of scouting, 95 assets had been identified that met the client’s search criteria and discussions with 15 asset owners had been initiated. Alacrita provided a final draft of the asset scouting database and met with the client to discuss our conclusions and next steps.
Explore Our Asset Scouting & In-Licensing Services
Alacrita supports both large pharma and biotech companies with their search and evaluation activities. Our asset scouting support is often structured to integrate with the client’s internal efforts, resulting in a constant flow of new opportunities.